Ernexa Therapeutics Inc. Warrants

Ernexa Therapeutics Inc. is a preclinical-stage company developing induced mesenchymal stem cell (iMSC) therapies for cancer and autoimmune diseases. Its lead candidates are ERNA-101, an allogeneic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for ovarian cancer, and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for rheumatoid arthritis. The company has a license agreement with Factor Bioscience Limited. Formerly known as Eterna Therapeutics Inc., it changed its name to Ernexa Therapeutics in March 2025. Founded in 2018, it is based in Cambridge, Massachusetts.